Phase 2 Trial of Adoptive Cell Therapy with TILs Plus IL-2
Phase 2
170
about 14 years
18–72
1 site in MD
About this study
This trial is testing a new treatment for melanoma. It involves taking cells from your tumors, growing them in the lab, and then returning them to you. Researchers are also investigating if adding pembrolizumab might improve this therapy's effectiveness.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive young TIL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Response rate
Secondary: Frequency and severity of treatment-related adverse events, Objective response rate (ORR), progression free survival (PFS) and safety (Cohort 3, Arm 3), Overall survival, Overall survival (Cohort 3, Arm 3)
Oncology